Metastatic Colorectal Cancer (mCRC) Market Forecast 2034

Publish Date: 05-Dec-2024

Pages : 200 Report Code : DRA1224004 Format :

Request Sample Report

Overview
TOC

Key Insights
2. Report Introduction
3. Metastatic Colorectal Cancer (mCRC) Market Overview at a Glance
3.1. Market Share (%) Distribution of mCRC in 2019
3.2. Market Share (%) Distribution of mCRC in 2032
4. Executive Summary of Metastatic Colorectal Cancer (mCRC)
4.1. Key Events
5. Epidemiology and Market Methodology
6. Disease Background and Overview
6.1. Introduction
6.2. Causes
6.3. Symptoms
6.4. CRC Staging
6.5. Risk Factors of CRC
6.6. Molecular Subtypes of CRC
6.7. Mechanisms of Metastasis in CRC
6.8. Drug Resistance in mCRC
6.9. Clinical Presentation of mCRC
6.10. Unusual Sites of Metastasis in CRC
6.10.1. Uterine Metastasis
6.10.2. Penile Metastasis
6.10.3. Scrotal Metastasis
6.10.4. Prostatic Metastasis
6.10.5. Bladder Metastasis
6.10.6. Peritoneal Pseudomyxoma
6.10.7. Abdominal Wall Metastasis
6.10.8. Bone Metastasis
6.10.9. Carcinomatous Lymphangitis
6.10.10. Adenopathies
6.10.11. Pancreatic Metastasis
6.11. Biomarkers in mCRC
6.11.1. Prognostic Biomarkers
6.11.2. Patient-Related Factors
6.11.3. Tumor-related Factors
6.11.4. Predictive Biomarkers
6.11.5. Markers to Predict 5-FU Response and Toxicity
6.11.6. Predicting Response to EGFR Therapy
6.11.7. Predicting Response to VEGF Inhibitors
6.11.8. Technology-Facilitated Biomarkers
6.12. Diagnosis
6.12.1. Clinical symptoms
6.12.2. Endoscopy
6.12.3. Imaging
6.12.4. Laboratory
6.12.5. Pathology
6.12.6. Biopsy
6.12.7. Molecular Testing of the Tumor
6.12.8. Blood Tests
6.12.9. Tumor-based Tests
6.12.10. Diagnosis of colorectal liver metastasis
7. Recognized Establishments
8. Treatment of Metastatic Colorectal Cancer (mCRC)
8.1. Initial/First-line Treatment of mCRC
8.2. Second and Third-line Treatment of mCRC
8.3. Therapies using medication
8.4. Surgery
8.5. Adjuvant therapy
8.6. Follow-up
8.7. Palliation
8.8. Maintenance Therapy
8.9. Treatment of Colon Cancer That Has Metastasized to a Single Site
9. Treatment of Patients with Late-stage Colorectal Cancer: ASCO Resource-Stratified Guideline (2020)
10. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer (2016)
10.1. Recommendations
10.1.1. Recommendation 1: Tissue handling
10.1.2. Recommendation 2: A selection of specimens for biomarker testing
10.1.3. Recommendation 3: Tissue selection
10.1.4. Recommendation 4: RAS testing
10.1.5. Recommendation 5: BRAF testing
10.1.6. Recommendation 6: MSI testing
10.1.7. Recommendation 7: Biomarkers of chemotherapy sensitivity and toxicity
10.1.8. Recommendation 8: Emerging biomarkers not recommended for routine patient management outside of a clinical trial setting
10.1.9. Recommendation 9: Emerging technologies
10.1.10. Recommendation 10: OMD
10.1.11. Recommendation 11: Imaging in the identification and management of disease
10.1.12. Recommendation 12: Perioperative treatment
10.1.13. Recommendation 13: Conversion therapy
10.1.14. Recommendation 14: Ablative techniques
10.1.15. Recommendation 15: Local ablation techniques
10.1.16. Recommendation 16: Embolization
10.1.17. Recommendation 17: Cytoreductive surgery and HIPEC
10.1.18. Recommendation 18: First-line systemic therapy combinations according to the targeted agent used
10.1.19. Recommendation 19: Maintenance therapy
10.1.20. Recommendation 20: Second-line combinations with targeted agents
10.1.21. Recommendation 21: Third-line therapy
10.2. Consensus recommendations on the use of cytotoxics and biologicals in the first- and subsequent-line treatment of patients with mCRC
10.2.1. Consensus recommendation for patients where cytoreduction with 'conversion' and/or the integration of local ablative treatment is the goal
10.2.2. Consensus recommendation for patients where cytoreduction is needed because of aggressive biology and/or risk of developing or existing severe symptoms
10.2.3. Consensus recommendation for patients where disease control is the goal
11. National Institute for Health and Care Excellence (NICE) Guidelines: Colorectal Cancer (2020)
11.1. Management of metastatic disease
11.1.1. People with asymptomatic primary tumor
11.1.2. People with mCRC in the liver
11.1.3. People with metastatic colorectal cancer in the lung
11.1.4. People with metastatic colorectal cancer in the peritoneum
11.2. Ongoing care and support
11.2.1. Follow-up for detection of local recurrence and distant metastases
12. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM) (2016)
12.1. Metastatic CRC Treatment Recommendations
12.1.1. Evaluation of elderly patients
12.1.2. Surgery for advanced disease
12.1.3. Locoregional treatments
13. Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG)
13.1. Recommendations on palliative chemotherapy indication for older patients with mCRC
13.2. Recommendations for cytotoxic chemotherapy in older patients:
13.3. Anti-angiogenic recommendations for older:
13.4. Recommendations for anti-EGFR, regorafenib and trifluridinetipiracil in older patients:
14. Spanish Society of Medical Oncology (SEOM) clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)
15. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines for the treatment of colorectal cancer- 2019
15.1. Treatment strategies for Stage IV CRC
15.2. Treatment strategies for hematogenous metastases
15.2.1. Treatment strategies for liver metastases
15.2.2. Treatment strategies for brain metastases
15.2.3. Treatment strategies for hematogenous metastases to other organs
16. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Colon and Rectal Cancer (2021)
17. Epidemiology and Patient Population
17.1. Key Findings
17.2. Epidemiology of Metastatic Colorectal Cancer (mCRC)
17.3. Epidemiology Scenario
17.3.1. Total Incident Cases of Colorectal Cancer (CRC)
17.3.2. Total Incident Cases of Metastatic Colorectal Cancer (mCRC)
18. Patient Journey
19. Key Endpoints in Metastatic Colorectal Cancer (mCRC)
20. Marketed Therapies
20.1. Key Cross
20.2. Keytruda (pembrolizumab): Merck
20.2.1. Drug Description
20.2.2. Regulatory Milestones
20.2.3. Other Developmental Activities
20.2.4. Pivotal Clinical Trial
20.2.5. Ongoing Current Pipeline Activity
20.2.6. Safety and Efficacy
20.3. Stivarga (Regorafenib): Alexion Pharmaceuticals
20.3.1. Drug Description
20.3.2. Regulatory Milestones
20.3.3. Other Developmental Activities
20.3.4. Pivotal Clinical Trial
20.3.5. Ongoing Current Pipeline Activity
20.3.6. Safety and Efficacy
20.4. Jemperli (dostarlimab): GlaxoSmithKline (GSK)
20.4.1. Drug Description
20.4.2. Regulatory Milestones
20.4.3. Pivotal Clinical Trial
20.5. Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib): Array BioPharma/ Pfizer + Pfizer
20.5.1. Drug Description
20.5.2. Regulatory Milestones
20.5.3. Other Developmental Activities
20.5.4. Pivotal Clinical Trial
20.5.5. Ongoing Current Pipeline Activity
20.5.6. Safety and Efficacy
20.6. Cyramza (ramucirumab): Eli Lilly
20.6.1. Drug Description
20.6.2. Regulatory Milestones
20.6.3. Other Developmental Activities
20.6.4. Pivotal Clinical Trial
20.6.5. Ongoing Current Pipeline Activity
20.6.6. Safety and Efficacy
20.7. Lonsurf (TAS-102): Taiho Oncology
20.7.1. Drug Description
20.7.2. Regulatory Milestones
20.7.3. Other Developmental Activities
20.7.4. Pivotal Clinical Trial
20.7.5. Ongoing Current Pipeline Activity
20.7.6. Safety and Efficacy
20.8. Opdivo (nivolumab) + Yervoy (ipilimumab): Bristol-Myers Squibb
20.8.1. Drug Description
20.8.2. Regulatory Milestones
20.8.3. Pivotal Clinical Trial
20.8.4. Ongoing Current Pipeline Activity
20.8.5. Safety and Efficacy
20.9. Vectibix (panitumumab) + Folfox/Chemotherapy: Amgen
20.9.1. Drug Description
20.9.2. Regulatory Milestones
20.9.3. Other Developmental Activities
20.9.4. Pivotal Clinical Trial
20.9.5. Ongoing Current Pipeline Activity
21. Emerging Therapies
21.1. Key Cross
21.2. Adagrasib (MRTX849) + cetuximab: Mirati Therapeutics + Merck
21.2.1. Product Description
21.2.2. Other Development Activities
21.2.3. Clinical Development
21.2.4. Safety and Efficacy
21.3. MK-4280A (favezelimab and pembrolizumab): Merck
21.3.1. Product Description
21.3.2. Other Development Activities
21.3.3. Clinical Development
21.3.4. Safety and Efficacy
21.4. Lynparza (olaparib) ± bevacizumab: Merck
21.4.1. Product Description
21.4.2. Other Development Activities
21.4.3. Clinical Development
21.5. Elunate (fruquintinib/HMPL-013): Hutchison Medipharma
21.5.1. Product Description
21.5.2. Other Development Activities
21.5.3. Clinical Development
21.5.4. Safety and Efficacy
21.6. Corsela (trilaciclib): G1 Therapeutics
21.6.1. Product Description
21.6.2. Other Development Activities
21.6.3. Clinical Development
21.7. Lenvima (lenvatinib/MK-7902/E7080) + Keytruda (pembrolizumab): Merck/Eisai
21.7.1. Product Description
21.7.2. Other Development Activities
21.7.3. Clinical Development
21.7.4. Safety and Efficacy
21.8. Modufolin (arfolitixorin): Isofol Medical
21.8.1. Product Description
21.8.2. Other Development Activities
21.8.3. Clinical Development
21.8.4. Safety and Efficacy
21.9. Lumakras (sotorasib) + Vectibix (panitumumab): Amgen
21.9.1. Product Description
21.9.2. Other Development Activities
21.9.3. Clinical Development
21.9.4. Safety and Efficacy
21.10. Masitinib: AB Science
21.10.1. Product Description
21.10.2. Other Development Activities
21.10.3. Clinical Development
21.11. Numidargistat (INCB001158): Incyte Corporation
21.11.1. Product Description
21.11.2. Other Development Activities
21.11.3. Clinical Development
21.11.4. Safety and Efficacy
21.12. Enhertu (trastuzumab deruxtecan): Daiichi Sankyo/AstraZeneca
21.12.1. Product Description
21.12.2. Other Development Activities
21.12.3. Clinical Development
21.12.4. Safety and Efficacy
21.13. Keytruda (pembrolizumab) + ibrutinib: Merck/Janssen
21.13.1. Product Description
21.13.2. Other Development Activities
21.13.3. Clinical Development
21.13.4. Safety and Efficacy
21.14. Onvansertib: Cardiff oncology
21.14.1. Product Description
21.14.2. Other Development Activities
21.14.3. Clinical Development
21.14.4. Safety and Efficacy
21.15. RRx-001: EpicentRx
21.15.1. Product Description
21.15.2. Clinical Development
21.15.3. Safety and Efficacy
21.16. Lenvima (lenvatinib) + pembrolizumab: Merck/Eisai
21.16.1. Product Description
21.16.2. Other Development Activities
21.16.3. Clinical Development
21.16.4. Safety and Efficacy
21.17. Tukysa (tucatinib) ± Herceptin (trastuzumab): Seagen + Roche
21.17.1. Product Description
21.17.2. Other Development Activities
21.17.3. Clinical Development
21.17.4. Safety and Efficacy
21.18. NT-17/GX-I7 (efineptakin Alfa) + Keytruda (pembrolizumab): NeoImmuneTech (Genexine) + Merck
21.18.1. Product Description
21.18.2. Other Development Activities
21.18.3. Clinical Development
21.18.4. Safety and Efficacy
21.19. BDTX-189: Black Diamond Therapeutics
21.19.1. Product Description
21.19.2. Other Development Activities
21.19.3. Clinical Development
21.20. Magrolimab + Erbitux (cetuximab): Gilead Sciences + Eli Lilly and Company
21.20.1. Product Description
21.20.2. Other Development Activities
21.20.3. Clinical Development
21.20.4. Safety and Efficacy
21.21. ONCOS-102 + IMFINZI (durvalumab): Ludwig Institute for Cancer Research + Targovax ASA
21.21.1. Product Description
21.21.2. Other Development Activities
21.21.3. Clinical Development
21.21.4. Safety and Efficacy
22. Metastatic Colorectal Cancer (mCRC): 7 Major Market Analysis
22.1. Key Findings
22.2. Market Outlook
22.2.1. Prescription Pattern Analysis
22.2.2. Emerging Drugs Analysis
22.3. Market Size of Metastatic Colorectal Cancer
22.3.1. Total Market Size of Metastatic Colorectal Cancer (mCRC)
22.3.2. Market Size of Metastatic Colorectal Cancer (mCRC) by Therapies
23. Market Access and Reimbursement
24. KOL Views
25. Market Drivers
26. Market Barriers
27. SWOT Analysis
28. Unmet Needs
29. Appendix
29.1. Bibliography
29.2. Report Methodology
30. DelveInsight Capabilities
31. Disclaimer
32. About DelveInsight

Choose the Right License for Your Needs

Pick the license that best suits your preferences and business objectives.

Single User License $ 1800 This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the

Multi User License $ 2350 This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the

Enterprise User License $ 2849 This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the

Buy Now

Add to cart

Metastatic Colorectal Cancer (mCRC) Market Overview (2023–2034)

Choose the Right License for Your Needs

Browse links

We accept

contact